Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00869622 · ClinicalTrials.gov registry record · Phase 4
Antiepileptic Drugs and Osteoporotic Prevention Trial
A Phase 4 study, sponsored by Boston VA Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT00869622 is a Phase 4 study that has completed, run by Boston VA Research Institute. The registered enrollment target is 80 participants.
The verdict
NCT00869622, a Phase 4 study, has completed, sponsored by Boston VA Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
Study Design: (e.g., Controlled, Double-Blind, Randomized, Parallel): Randomized, double-blind, placebo controlled of a bisphosphonate in the prevention of bone loss associated with the use of antiepileptic drugs.
Interventions
- DRUG Risedronate
- DRUG Placebo + Calcium and Vitamin D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2006-06 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00869622
The ClinicalTrials.gov registry entry for NCT00869622 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston VA Research Institute, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Risedronate is the first listed.
NCT00869622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00869622 about?
NCT00869622 is a clinical study titled "Antiepileptic Drugs and Osteoporotic Prevention Trial". Study Design: (e.g., Controlled, Double-Blind, Randomized, Parallel): Randomized, double-blind, placebo controlled of a bisphosphonate in the prevention of bone loss associated with the use of antiepileptic drugs.
What is the current status of trial NCT00869622?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2006-06. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00869622?
The interventions under investigation include: Risedronate (DRUG), Placebo + Calcium and Vitamin D (DRUG).
Who is sponsoring clinical trial NCT00869622?
This trial is sponsored by Boston VA Research Institute, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.